

CURRICULUM VITAE

Rubén Bravo Valverde, M.D.

Forensic and Geriatric Psychiatrist
Centro Especializado de Psiquiatría
1995 Road 2 Suite 1209-1210 Bayamón, Puerto Rico 00959-1201
Telephones: (787) 786-0575/780-3752
Fax: (787) 787-0412 Cellular: (787) 553-1411
Email: rubenbravo@earthlink.net

Medical Licenses

Puerto Rico: 14240
Florida PAT: 9100771
New York LP: 01173

Academic History

University of Columbia Missouri
Department of Psychiatry and Neurology

University of Miami Jackson Memorial Hospital
Department of Psychiatry

State of New York Health Science Center Syracuse New
York
Department of Forensic Psychiatry

University of Mimi Jackson Memorial Hospital
Department of Geriatric Psychiatry

Universidad Central del Este, Dominican Republic
Doctor in Medicine

City College, New York

Manhattan Community College, New York

Colegio Pedro Vicente Maldonado, Ecuador

Appointments Held

Vice-President of Geriatric Chapter APA Puerto Rico

Advisory Board Bristol Meyer Pharmaceutical

Advisory Board Wyeth Pharmaceutical

Advisory Board Pfizer Pharmaceutical

Bayamón Psychiatric Association
President & Founder

Fellowship: Geriatric Psychiatry
Jackson Memorial Hospital, Miami, Florida

Fellowship: Forensic Psychiatry
SUNY, Syracuse, New York

Residence: Department of Psychiatry
Jackson Memorial Hospital, Miami, Florida

PGY1, Psychiatry and Neurology Department
University Hospital, Columbia, Missouri

Bayamon Psychiatric Association:
President Executive Committee

Puerto Rico School of Physicians and Surgeons
Forensic Psychiatrist Delegate

Vice-President Geriatric Psychiatric Chapter Puerto Rico
School of Medical Surgeons

President Chapter of Geriatric Psychiatry Chapter Puerto
Rico School of Medical Surgeons

Editorial Duties

- 1997 Compliance with Medical Treatments in Patients with Alzheimer Disease
- 1984-1992 Valerian Extract and its Hypnotic Properties in a Hispanic Population Cultural Diversity with Ethnic Minority Psychology Volume 6 Number 1

Experience

- 2004- Present Caribbean Education and Research Center
Metro Medical Center
1995 Road 2 Suite 1209-1210 Bayamón, Puerto Rico 00959-1201
Research Group Principal Investigator
Conduct research
- 2002-Present Centro Especializado en Psiquiatría, Bayamón, Puerto Rico
Private Practice
- 2000-2002 Binghamton Psychiatry Center, Binghamton, New York
Admissions Department
- Performing psychiatric services in a State facility concerned with the care and treatment of the mentally ill.
 - Responsible for inpatient treatment, making diagnosis, prescribing and applying treatment, overseeing the care of the patients by medical, nursing, social service, ward and other personnel.
 - Identifying improved patients and making recommendations concerning their discharge or transfer to convalescent status to insure reintegration of the patient into the community.
- 1997-1999 Central New York Psychiatric Center, Marcy, New York
Forensic Psychiatrist, Admissions Department
- Performing civil forensic psychiatry, competency civil and criminal, right to treatment, right to refuse treatment, psychiatry malpractice.
 - Criminal forensic psychiatry, no impact cases, landmark cases, psychiatry and Tort law cases.
 - Insanity defense, involuntary hospitalization, privilege and confidentiality, juvenile law.
- 1994-1997 Miami Mental Health Associates, Miami, Florida

1988-1993

Jackson Memorial Hospital, Miami, Florida

Affiliations

American Psychiatry Association 76985

American Forensic Association 79136

American Geriatric Association

American Medical Association

Fellow, Inter-American College of Physicians and Surgeons

Research

Novartis

Clinical Trial Protocol CAG0178C2302

An 8-week, randomized, double-blind, placebo-controlled, parallel-group, multi-center study of the efficacy and safety of agomelatine 0.5mg and 1mg sublingual tablets administered once daily in patients with Major Depressive Disorder (MDD)
Sub-Investigator

Clinical Trial Protocol CAG0178C2399

A 52-Week, multi-center, open-label study of the safety and tolerability of agomelatine sublingual tablets in patients with Major Depressive Disorder (MDD)
Principal Investigator

A 24 Week Open-Label Extension to Study CENA713DSU44:
A 24 Week, Prospective, Randomized, Parallel-Group, Double-Blind, Multi-Center Study Comparing the Effects of Rivastigmine Patch 15 cm² vs. Rivastigmine Patch 5 cm² on Activities of Daily Living and Cognition in Patients with Severe Dementia of the Alzheimer's Type (ACTION).
Principal Investigator

A 24 Week, Prospective, Randomized, Parallel-Group, Double-Blind, Multi Center Study Comparing the Effects of Rivastigmine Patch 15cm² vs. Rivastigmine Patch 5cm² on Activities of Daily Living and Cognition in Patients with Severe Dementia of the Alzheimer Type.
Principal Investigator

An 8-week, randomized, double-blind, fixed-dosage, placebo controlled, parallel-group, multi-center study of the efficacy, safety and tolerability of agomelatine 25mg and 50mg in the treatment of Major Depressive Disorder (MDD) followed by a 52 week, open-label extension.

Principal Investigator

Clinical Research on Alzheimer's Medication (New Application)

Principal Investigator

Trial entitled: A 24 week, multi-center, randomized, Double-blind Placebo and Active-controlled, Parallel group. Evaluation of the Efficacy, Safety and Tolerability of the once daily Exelon Patch Formulation in patients with probable Alzheimer Disease. (MMSE 10-20)

Principal Investigator

Post Text Supplement 1-Open-label Extension to Protocol CENA713D 2320: An open-label, 28-week Extension to a 24-week, Multicenter, Randomized, Double-blind, Placebo-and Active controlled, Parallel-group Evaluation of the Efficacy, Safety, and tolerability of the Once Once-daily Exelon Patch Formulation in Patients with Probable Alzheimer's Disease (MMSE 10-20)

Principal Investigator

Alzheimer Disease A prospective, 26 week, open-label, multi-center, single arm pilot study to evaluate the safety and tolerability of Exelone® Capsule with add on Memantine HCl in patients with probable Alzheimer's Disease (MMSE 10-20)

Protocol: CENA713D US38

Principal Investigator

Alzheimer Disease

A prospective, open-label, randomized, multi-center, parallel group study of five weeks, with a 20 week extension evaluating the tolerability and safety of switching from Donepezil to an Initial Dose of 5cm² Rivastigmine Patch Formulation in patients with probable Alzheimer Disease

Principal Investigator

Lilly

Double-Blind, Randomized, Placebo-controlled Study to Evaluate the Safety and Efficacy of ABT-925 in subjects with Acute Exacerbations of Schizophrenia.

Principal Investigator

Medication Studies on Bipolar/Schizoaffective Disorder

Principal Investigator

Schizophrenia An International Multi-center Large Trial (LST) to compare the Cardiovascular Safety and Efficacy of Ziprasidone and Olanzapine in patients with Schizophrenia.
Principal Investigator

Pfizer Zodiac

Medication Studies on Schizophrenia
Principal Investigator

Double-Blind, Randomized, Placebo Controlled Study to evaluate the safety and efficacy of ABT-925 in subjects with Acute Exacerbations of Schizophrenia
Principal Investigator

Gastrointestinal Study Randomized event and safety open label NSAID Study (GI Reasons): A randomized open label blinded-end-point, parallel group trial of GI safety of Celecoxib compared with non-selective, non steroidal anti-inflammatory drugs (NSAID) in Osteoarthritis patients.
Principal Investigator

Seminars and Presentations

Speaker for Jansen Pharmaceutical

Speaker for Pfizer Pharmaceutical

Speaker for AstraZeneca Pharmaceutical

2004-2005

Psychiatric Congress of the Bayamón Psychiatrist Association

Speaker for Novartis Pharmaceuticals

Honors Received

2003

Distinguished Citizen of San Juan, Puerto Rico
Mayor of San Juan Jorge Santini

2004

Distinguished Psychiatrist of Puerto Rico
Colegio de Abogados de Puerto Rico

2005

Universidad Central del Este
San Pedro de Macoris, Dominican Republic
Honor Alumni